The Role of the Paralogs CBP and P300 in Androgen Receptor Function and Prostate Cancer

Abstract

Multiple lines of evidence suggest the importance of the paralogs EP300 and CBP in advanced prostate cancer, and drug development efforts are underway to create efficacious small molecule inhibitors of the proteins. A greater understanding of the behavior of EP300 and CBP including how they relate to the Androgen Receptor in prostate cancer is critically needed, especially given ongoing clinical trials attempting to target these proteins in advanced prostate cancer, often in combination with or after the administration other anti-androgen therapies such as enzalutamide. This grant proposes to define the cistrome of EP300 and CBP in prostate cancer models, delineate the functional differences between CBP and EP300 through chemical and genetic perturbations, and determine the impact of mutations within the bromodomain and acetyltransferase domains ofEP300 and CBP as well as clinically-identified mutations on protein function and drug response.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2022
Accession Number
AD1190925

Entities

People

  • Alok K. Tewari

Organizations

  • Dana–Farber Cancer Institute

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Antibodies
  • Biomedical Research
  • Cell Line
  • Cells
  • Clinical Trials
  • Department Of Defense
  • Inhibitors
  • Maryland
  • Neoplasms
  • Professional Development
  • Prostate
  • Prostate Cancer
  • Proteins
  • Small Molecules
  • Technology Transfer

Fields of Study

  • Biology

Readers

  • Oncology
  • Prostate Cancer Biology.
  • Traumatic Brain Injury (TBI) and Cognitive Aging in the Guam and Border Populations Affected by Alzheimer's Disease and Tau-Associated Dementias.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech